Impaired plasmalogens in patients with schizophrenia
Plasmalogens are a subclass of glycerophospholipids and ubiquitous constituents of cellular membranes and serum lipoproteins. Several neurological disorders show decreased level of plasmogens. An earlier study found differences in plasma phospholipids between unmedicated patients with schizophrenia...
Saved in:
| Published in | Psychiatry research Vol. 198; no. 3; pp. 347 - 352 |
|---|---|
| Main Authors | , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Kidlington
Elsevier Ireland Ltd
15.08.2012
Elsevier |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0165-1781 1872-7123 1872-7123 |
| DOI | 10.1016/j.psychres.2012.02.019 |
Cover
Loading…
| Abstract | Plasmalogens are a subclass of glycerophospholipids and ubiquitous constituents of cellular membranes and serum lipoproteins. Several neurological disorders show decreased level of plasmogens. An earlier study found differences in plasma phospholipids between unmedicated patients with schizophrenia and matched healthy control subjects. We here report a comparison of plasma plasmalogen levels across 20 drug-naïve patients experiencing first psychotic episodes, 20 recently unmedicated patients experiencing psychotic relapses after failing to comply with prescribed medications, and 17 matched healthy control subjects.
Multiple plasma phosphatidylcholine and phosphatidylethanolamine plasmalogen levels were significantly lower in first episode patients and patients with recurrent disease compared to healthy controls. Reduced plasmalogen levels appear to be a trait evident at the onset of psychotic illness and after multiple psychotic relapses. It is implied that reductions in plasmalogen levels are not related to antipsychotic treatment but due to the illness itself. Reduced plasmalogen levels suggest impairments in membrane structure and function in patients with schizophrenia that might happen early in development. This may serve as a clue to the neurobiology of schizophrenia and should be studied as a potential biomarker for individuals at risk for schizophrenia. |
|---|---|
| AbstractList | Abstract Plasmalogens are a subclass of glycerophospholipids and ubiquitous constituents of cellular membranes and serum lipoproteins. Several neurological disorders show decreased level of plasmogens. An earlier study found differences in plasma phospholipids between unmedicated patients with schizophrenia and matched healthy control subjects. We here report a comparison of plasma plasmalogen levels across 20 drug-naïve patients experiencing first psychotic episodes, 20 recently unmedicated patients experiencing psychotic relapses after failing to comply with prescribed medications, and 17 matched healthy control subjects. Multiple plasma phosphatidylcholine and phosphatidylethanolamine plasmalogen levels were significantly lower in first episode patients and patients with recurrent disease compared to healthy controls. Reduced plasmalogen levels appear to be a trait evident at the onset of psychotic illness and after multiple psychotic relapses. It is implied that reductions in plasmalogen levels are not related to antipsychotic treatment but due to the illness itself. Reduced plasmalogen levels suggest impairments in membrane structure and function in patients with schizophrenia that might happen early in development. This may serve as a clue to the neurobiology of schizophrenia and should be studied as a potential biomarker for individuals at risk for schizophrenia. Plasmalogens are a subclass of glycerophospholipids and ubiquitous constituents of cellular membranes and serum lipoproteins. Several neurological disorders show decreased level of plasmogens. An earlier study found differences in plasma phospholipids between unmedicated patients with schizophrenia and matched healthy control subjects. We here report a comparison of plasma plasmalogen levels across 20 drug-naïve patients experiencing first psychotic episodes, 20 recently unmedicated patients experiencing psychotic relapses after failing to comply with prescribed medications, and 17 matched healthy control subjects. Multiple plasma phosphatidylcholine and phosphatidylethanolamine plasmalogen levels were significantly lower in first episode patients and patients with recurrent disease compared to healthy controls. Reduced plasmalogen levels appear to be a trait evident at the onset of psychotic illness and after multiple psychotic relapses. It is implied that reductions in plasmalogen levels are not related to antipsychotic treatment but due to the illness itself. Reduced plasmalogen levels suggest impairments in membrane structure and function in patients with schizophrenia that might happen early in development. This may serve as a clue to the neurobiology of schizophrenia and should be studied as a potential biomarker for individuals at risk for schizophrenia.Plasmalogens are a subclass of glycerophospholipids and ubiquitous constituents of cellular membranes and serum lipoproteins. Several neurological disorders show decreased level of plasmogens. An earlier study found differences in plasma phospholipids between unmedicated patients with schizophrenia and matched healthy control subjects. We here report a comparison of plasma plasmalogen levels across 20 drug-naïve patients experiencing first psychotic episodes, 20 recently unmedicated patients experiencing psychotic relapses after failing to comply with prescribed medications, and 17 matched healthy control subjects. Multiple plasma phosphatidylcholine and phosphatidylethanolamine plasmalogen levels were significantly lower in first episode patients and patients with recurrent disease compared to healthy controls. Reduced plasmalogen levels appear to be a trait evident at the onset of psychotic illness and after multiple psychotic relapses. It is implied that reductions in plasmalogen levels are not related to antipsychotic treatment but due to the illness itself. Reduced plasmalogen levels suggest impairments in membrane structure and function in patients with schizophrenia that might happen early in development. This may serve as a clue to the neurobiology of schizophrenia and should be studied as a potential biomarker for individuals at risk for schizophrenia. Plasmalogens are a subclass of glycerophospholipids and ubiquitous constituents of cellular membranes and serum lipoproteins. Several neurological disorders show decreased level of plasmogens. An earlier study found differences in plasma phospholipids between unmedicated patients with schizophrenia and matched healthy control subjects. We here report a comparison of plasma plasmalogen levels across 20 drug-naïve patients experiencing first psychotic episodes, 20 recently unmedicated patients experiencing psychotic relapses after failing to comply with prescribed medications, and 17 matched healthy control subjects. Multiple plasma phosphatidylcholine and phosphatidylethanolamine plasmalogen levels were significantly lower in first episode patients and patients with recurrent disease compared to healthy controls. Reduced plasmalogen levels appear to be a trait evident at the onset of psychotic illness and after multiple psychotic relapses. It is implied that reductions in plasmalogen levels are not related to antipsychotic treatment but due to the illness itself. Reduced plasmalogen levels suggest impairments in membrane structure and function in patients with schizophrenia that might happen early in development. This may serve as a clue to the neurobiology of schizophrenia and should be studied as a potential biomarker for individuals at risk for schizophrenia. Plasmalogens are a subclass of glycerophospholipids and ubiquitous constituents of cellular membranes and serum lipoproteins. Several neurological disorders show decreased level of plasmogens. An earlier study found differences in plasma phospholipids between unmedicated patients with schizophrenia and matched healthy control subjects. We here report a comparison of plasma plasmalogen levels across 20 drug-naïve patients experiencing first psychotic episodes, 20 recently unmedicated patients experiencing psychotic relapses after failing to comply with prescribed medications, and 17 matched healthy control subjects. Multiple plasma phosphatidylcholine and phosphatidylethanolamine plasmalogen levels were significantly lower in first episode patients and patients with recurrent disease compared to healthy controls. Reduced plasmalogen levels appear to be a trait evident at the onset of psychotic illness and after multiple psychotic relapses. It is implied that reductions in plasmalogen levels are not related to antipsychotic treatment but due to the illness itself. Reduced plasmalogen levels suggest impairments in membrane structure and function in patients with schizophrenia that might happen early in development. This may serve as a clue to the neurobiology of schizophrenia and should be studied as a potential biomarker for individuals at risk for schizophrenia. |
| Author | Nimgaonkar, Vishwajit L. Georgiades, Anastasia Kaddurah-Daouk, Rima Zhu, Hongjie McEvoy, Joseph Keshavan, Matcheri S. Baillie, Rebecca Buckley, Peter F. Nasrallah, Henry A. K. Yao, Jeffrey |
| Author_xml | – sequence: 1 givenname: Rima surname: Kaddurah-Daouk fullname: Kaddurah-Daouk, Rima email: kaddu001@mc.duke.edu organization: Duke University Medical Center, Department of Psychiatry and Behavioral Sciences, DUMC Box 3950 Durham, NC 27710, USA – sequence: 2 givenname: Joseph surname: McEvoy fullname: McEvoy, Joseph organization: Duke University Medical Center, Department of Psychiatry and Behavioral Sciences, DUMC Box 3950 Durham, NC 27710, USA – sequence: 3 givenname: Rebecca surname: Baillie fullname: Baillie, Rebecca organization: Rosa & Co. LLC, 751 Laurel St., Suite 127, San Carlos, CA 94070, USA – sequence: 4 givenname: Hongjie surname: Zhu fullname: Zhu, Hongjie organization: Department of Statistics & Bioinformatics Research Center, North Carolina State University, Raleigh, NC 27695, USA – sequence: 5 givenname: Jeffrey surname: K. Yao fullname: K. Yao, Jeffrey organization: VA Pittsburgh Healthcare System, Pittsburgh, PA 15206, USA – sequence: 6 givenname: Vishwajit L. surname: Nimgaonkar fullname: Nimgaonkar, Vishwajit L. organization: Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA – sequence: 7 givenname: Peter F. surname: Buckley fullname: Buckley, Peter F. organization: Department of Psychiatry, Medical College of Georgia, Augusta, GA 30912, USA – sequence: 8 givenname: Matcheri S. surname: Keshavan fullname: Keshavan, Matcheri S. organization: Department of Psychiatry, Harvard Medical School, Boston, MA 02115, USA – sequence: 9 givenname: Anastasia surname: Georgiades fullname: Georgiades, Anastasia organization: Duke University Medical Center, Department of Psychiatry and Behavioral Sciences, DUMC Box 3950 Durham, NC 27710, USA – sequence: 10 givenname: Henry A. surname: Nasrallah fullname: Nasrallah, Henry A. organization: Department of Psychiatry, University of Cincinnati, College of Medicine, Cincinnati, OH 45219, USA |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=26631529$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/22513041$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkk2LFDEQhoOsuLOjf2Hpi-Clx1T6G0SUxY-FBQ_qOaSTipOxO2lTPcr4600zMwh7cIWCXJ73rVS9dcUufPDI2DXwDXCoX-42Ex30NiJtBAex4amge8RW0DYib0AUF2yVwCqHpoVLdkW045wL6Lon7FKICgpewoqVt-OkXESTTYOiUQ3hG3rKnM8mNTv0M2W_3LzNSG_d7zClht6pp-yxVQPhs9O7Zl_fv_ty8zG_-_Th9ubtXa4r3s65Bmx1Y60QxgihKq6E1XXR9oL3bddWdVPWWNrSNmVhu77tEUpeGGO6yoiusMWavTj6TjH82CPNcnSkcRiUx7AnCVBBs0xVJ_T6hO77EY2cohtVPMjzpAl4fgIUaTXYqLx29Jer6wKq1HXNXh05HQNRRCu1m9Mqgp-jcoMELpcA5E6eA5BLAJKngkVe35OfOzwofHMUYlroT4dRkk7712hSOnqWJriHLV7fs9CD8y5N-x0PSLuwjz7FJUFSEsjPy3ks1wGC8-QL_zb4nx_8AeSxzU0 |
| CODEN | PSRSDR |
| CitedBy_id | crossref_primary_10_1007_s11306_024_02171_6 crossref_primary_10_1021_acs_analchem_5b00555 crossref_primary_10_1007_s11745_015_4068_y crossref_primary_10_1016_j_schres_2017_10_042 crossref_primary_10_3390_biom11050720 crossref_primary_10_1007_s00216_017_0336_4 crossref_primary_10_3390_membranes11110838 crossref_primary_10_1194_jlr_M081026 crossref_primary_10_3390_ijms251910266 crossref_primary_10_1007_s00216_015_9256_3 crossref_primary_10_3389_fcell_2022_946393 crossref_primary_10_1016_j_schres_2024_06_043 crossref_primary_10_1371_journal_pone_0068717 crossref_primary_10_1007_s11745_016_4170_9 crossref_primary_10_1016_j_eng_2023_04_012 crossref_primary_10_1016_j_jpsychires_2021_06_001 crossref_primary_10_1038_tp_2014_33 crossref_primary_10_1021_acs_jproteome_6b00628 crossref_primary_10_1111_cts_70195 crossref_primary_10_1194_jlr_P081620 crossref_primary_10_1016_j_bbalip_2014_11_005 crossref_primary_10_1038_tp_2016_142 crossref_primary_10_1080_15622975_2020_1769188 crossref_primary_10_1371_journal_pone_0167229 crossref_primary_10_3109_15622975_2015_1117656 crossref_primary_10_1021_ac403554h crossref_primary_10_1038_tp_2017_211 crossref_primary_10_1093_bib_bbx157 crossref_primary_10_1016_j_schres_2014_11_032 crossref_primary_10_1016_j_bbamem_2022_184033 crossref_primary_10_3390_metabo14090475 crossref_primary_10_1242_dmm_042499 crossref_primary_10_13070_mm_en_8_2665 crossref_primary_10_3389_fpsyt_2024_1463974 crossref_primary_10_1016_j_plabm_2018_01_003 crossref_primary_10_1016_j_biochi_2022_08_010 crossref_primary_10_3389_fpsyt_2021_642403 crossref_primary_10_1007_s00216_016_9812_5 crossref_primary_10_1016_j_brainresbull_2023_110702 crossref_primary_10_3389_fphar_2021_735196 crossref_primary_10_1016_j_bbamcr_2015_12_005 crossref_primary_10_1194_jlr_RA120000634 crossref_primary_10_1111_bdi_12422 crossref_primary_10_1093_schbul_sbu053 crossref_primary_10_1002_npr2_12368 crossref_primary_10_1001_jamapsychiatry_2022_4350 crossref_primary_10_1177_0269881114566631 crossref_primary_10_17816_CP101 crossref_primary_10_5665_sleep_5142 crossref_primary_10_1016_j_psychres_2024_116005 crossref_primary_10_3390_metabo14020080 crossref_primary_10_1016_j_brainres_2024_149132 crossref_primary_10_1002_rcm_7241 crossref_primary_10_1016_j_tem_2019_01_003 crossref_primary_10_1111_acps_12388 crossref_primary_10_17816_CP15488 crossref_primary_10_1016_j_pscychresns_2018_10_001 crossref_primary_10_1186_s12888_016_1006_3 crossref_primary_10_1016_j_psychres_2016_10_042 crossref_primary_10_21508_1027_4065_2021_66_4_16_24 crossref_primary_10_1002_1873_3468_12788 crossref_primary_10_1007_s00406_018_0971_6 crossref_primary_10_3389_fpsyt_2021_723158 |
| Cites_doi | 10.1016/j.plefa.2009.09.002 10.1093/ajcn/71.1.376s 10.1385/CT:1:4:253 10.1194/jlr.M200169-JLR200 10.1002/iub.91 10.1016/0005-2736(94)00227-4 10.1146/annurev.pharmtox.48.113006.094715 10.1073/pnas.1530509100 10.1093/ndt/13.10.2594 10.1054/mehy.2001.1511 10.1016/S0278-5846(00)00181-0 10.1093/ndt/gfh035 10.1016/S0920-9964(97)00151-5 10.1111/j.1471-4159.2007.04715.x 10.1016/0006-8993(95)00931-F 10.1371/journal.pone.0003863 10.1016/0165-1781(93)90032-C 10.1016/j.psychres.2009.01.009 10.1016/S0531-5565(99)00025-X 10.1007/978-1-59745-244-1_10 10.1016/0006-3223(91)90235-E 10.1021/bi0156557 10.2174/1567205052772786 10.1016/S0531-5565(98)00014-X 10.1016/S0006-3223(02)01549-4 10.1007/s11306-009-0174-2 10.1021/bi00328a014 10.1136/adc.2007.129817 10.1016/j.plefa.2005.07.007 10.1093/schbul/19.1.35 10.1038/sj.mp.4002000 10.59566/IJBS.2010.6225 10.1021/bi980303u 10.1016/0009-3084(96)02580-7 10.1194/jlr.M200363-JLR200 10.1371/journal.pone.0025482 10.2174/092986709788682164 10.1046/j.1432-1033.2003.03356.x 10.1177/107385840100700308 10.1042/bst0320141 10.1016/S0022-2275(20)32454-8 10.1038/nature09552 10.1093/oxfordjournals.schbul.a007140 10.1016/S0920-9964(99)00095-X 10.1016/S0952-3278(03)00084-X 10.1515/CCLM.2007.111 10.1021/bi00250a030 10.1038/clpt.2010.250 10.1007/s11745-005-1441-x 10.1046/j.1365-2990.1999.00162.x 10.1111/j.1471-4159.2010.07070.x 10.1194/jlr.P700023-JLR200 10.1056/NEJMoa051688 10.1016/j.plefa.2003.08.009 10.1038/npp.2008.174 10.1023/A:1011603916962 10.1016/S0021-9258(18)64849-5 10.1001/archpsyc.60.6.585 10.1016/j.psychres.2010.07.049 10.1016/S0006-291X(03)00157-8 10.1016/j.pnpbp.2006.07.010 10.1021/pr800188y |
| ContentType | Journal Article |
| Copyright | 2012 Elsevier Ltd Elsevier Ltd 2015 INIST-CNRS Copyright © 2012 Elsevier Ltd. All rights reserved. |
| Copyright_xml | – notice: 2012 Elsevier Ltd – notice: Elsevier Ltd – notice: 2015 INIST-CNRS – notice: Copyright © 2012 Elsevier Ltd. All rights reserved. |
| DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1016/j.psychres.2012.02.019 |
| DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1872-7123 |
| EndPage | 352 |
| ExternalDocumentID | 22513041 26631529 10_1016_j_psychres_2012_02_019 S0165178112001011 1_s2_0_S0165178112001011 |
| Genre | Journal Article |
| GroupedDBID | --- --K --M .1- .FO .~1 0R~ 123 1B1 1P~ 1RT 1~. 1~5 4.4 457 4G. 5VS 7-5 71M 8P~ 9JM 9JO AABNK AADFP AAEDT AAEDW AAGUQ AAIKJ AAKOC AALRI AAOAW AAQFI AATTM AAXKI AAXLA AAXUO ABBQC ABCQJ ABFNM ABIVO ABJNI ABMAC ABWVN ABXDB ACDAQ ACGFS ACHQT ACIEU ACIUM ACRLP ACRPL ACVFH ACXNI ADBBV ADCNI ADEZE ADMUD ADNMO AEBSH AEIPS AEKER AENEX AEUPX AEVXI AFPUW AFRHN AFTJW AFXIZ AGCQF AGHFR AGUBO AGWIK AGYEJ AHHHB AIEXJ AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX AXJTR BKOJK BLXMC BNPGV CS3 DU5 EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 F5P FDB FIRID FNPLU FYGXN G-Q GBLVA HZ~ IHE J1W KOM M29 M2V M39 M3V M41 MO0 MOBAO N9A O-L O9- OAUVE OH0 OKEIE OU- OZT P-8 P-9 P2P PC. Q38 ROL RPZ SAE SCC SDF SDG SDP SEL SES SNS SPCBC SPS SSB SSH SSN SSY SSZ T5K UV1 Z5R ZGI ~G- .GJ 29P 53G AACTN AAGJA AAGKA AAQXK ABMZM ABOYX ADVLN AFCTW AFJKZ AFKWA AJOXV AMFUW ASPBG AVWKF AZFZN FEDTE FGOYB G-2 HEG HMK HMO HMQ HMW HVGLF R2- RIG SEW WUQ AADPK AAIAV ABLVK ABYKQ AFYLN AJBFU EFLBG LCYCR ZA5 AAYWO AAYXX AGQPQ AGRNS AIGII APXCP CITATION AAPBV ABPIF ABPTK IQODW CGR CUY CVF ECM EIF NPM 7X8 |
| ID | FETCH-LOGICAL-c508t-c1e8c7ff22dd22a50a2fc638b20b89856746e4f4f743f9b8be1403ddd95d293f3 |
| IEDL.DBID | .~1 |
| ISSN | 0165-1781 1872-7123 |
| IngestDate | Fri Sep 05 06:46:58 EDT 2025 Thu Apr 03 06:57:19 EDT 2025 Sun Oct 22 16:04:59 EDT 2023 Tue Jul 01 03:29:45 EDT 2025 Thu Apr 24 23:06:02 EDT 2025 Fri Feb 23 02:33:50 EST 2024 Sun Feb 23 10:19:14 EST 2025 Tue Aug 26 16:31:36 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Keywords | Drug-naïve Metabolomics PC PE Plasmalogen Schizophrenia Lipidomics Phospholipids phosphatidylethanolamine phosphatidylcholine Psychosis Human Phospholipid Lipids |
| Language | English |
| License | https://www.elsevier.com/tdm/userlicense/1.0 CC BY 4.0 Copyright © 2012 Elsevier Ltd. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c508t-c1e8c7ff22dd22a50a2fc638b20b89856746e4f4f743f9b8be1403ddd95d293f3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| PMID | 22513041 |
| PQID | 1151700026 |
| PQPubID | 23479 |
| PageCount | 6 |
| ParticipantIDs | proquest_miscellaneous_1151700026 pubmed_primary_22513041 pascalfrancis_primary_26631529 crossref_citationtrail_10_1016_j_psychres_2012_02_019 crossref_primary_10_1016_j_psychres_2012_02_019 elsevier_sciencedirect_doi_10_1016_j_psychres_2012_02_019 elsevier_clinicalkeyesjournals_1_s2_0_S0165178112001011 elsevier_clinicalkey_doi_10_1016_j_psychres_2012_02_019 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2012-08-15 |
| PublicationDateYYYYMMDD | 2012-08-15 |
| PublicationDate_xml | – month: 08 year: 2012 text: 2012-08-15 day: 15 |
| PublicationDecade | 2010 |
| PublicationPlace | Kidlington |
| PublicationPlace_xml | – name: Kidlington – name: Ireland |
| PublicationTitle | Psychiatry research |
| PublicationTitleAlternate | Psychiatry Res |
| PublicationYear | 2012 |
| Publisher | Elsevier Ireland Ltd Elsevier |
| Publisher_xml | – name: Elsevier Ireland Ltd – name: Elsevier |
| References | Hartmann, Kuchenbecker, Grimm (bb0095) 2007; 103 Zivkovic, Wiest, Nguyen, Davis, Watkins, German (bb0330) 2009; 5 Reddy, Yao (bb0265) 2003; 69 Reddy, Keshavan, Yao (bb0260) 2004; 30 Hoerrmann, Donis, Sluga, Stutz, Paltauf (bb0120) 1991; 20 Brosche, Platt (bb0020) 1998; 33 Cheng, Xu, McKeel, Han (bb0335) 2003; 49 Pike, Han, Chung, Gross (bb0250) 2002; 41 Geppert, Min, Neville, Lowy, Ghebremeskel (bb0065) 2009; 82 Falkai, Honer, David, Bogerts, Majtenyi, Bayer (bb0050) 1999; 25 Yarlagadda (bb0320) 2002; 58 Andre, Juaneda, Sebedio, Chardigny (bb0010) 2005; 40 Keshavan, Mallinger, Pettegrew, Dippold (bb0165) 1993; 49 Lieberman, Stroup, McEvoy, Swartz, Rosenheck, Perkins, Keefe, Davis, Davis, Lebowitz, Severe, Hsiao (bb0185) 2005; 353 Engelmann, Brautigam, Kulschar, Duhm, Prenner, Hermetter, Richter, Thiery, Seidel (bb0040) 1994; 1196 Mahadik, Evans, Lal (bb0210) 2001; 25 Schwarz, Prabakaran, Whitfield, Major, Leweke, Koethe, McKenna, Bahn (bb0275) 2008; 7 Wang-Sattler, Yu, Mittelstrass, Lattka, Altmaier, Gieger, Ladwig, Dahmen, Weinberger, Hao, Liu, Li, Wichmann, Adamski, Suhre, Illig (bb0300) 2008; 3 Latorre, Collado, Fernandez, Aragones, Catalan (bb0175) 2003; 270 Stenvinkel, Diczfalusy, Lindholm, Heimburger (bb0280) 2004; 19 Kaddurah-Daouk, Baillie, Zhu, Zeng, Wiest, Nguyen, Wojnoonski, Watkins, Trupp, Krauss (bb0160) 2011; 6 Munn, Arnio, Liu, Zoeller, Liscum (bb0230) 2003; 44 Nuss, Tessier, Ferreri, De Hert, Peuskens, Trugnan, Masliah, Wolf (bb0235) 2009; 169 Lohner (bb0190) 1996; 81 Hashimoto, Hossain, Masumura (bb0100) 1999; 34 Maeba, Ueta (bb0200) 2004; 32 R Development Core Team (bb0350) 2006 Mahadik, Yao (bb0345) 2006 Gaposchkin, Zoeller (bb0060) 1999; 40 Insel (bb0135) 2010; 468 Pettegrew, Keshavan, Minshew (bb0240) 1993; 19 Martinez, Vazquez, Garcia-Silva, Manzanares, Bertran, Castello, Mougan (bb0215) 2000; 71 Gross (bb0085) 1985; 24 Kristal, Shurubor, Kaddurah-Daouk, Matson (bb0170) 2007; 358 Rhoades, Overall (bb0270) 1988; 24 Sumiyoshi, Higuchi, Matsui, Itoh, Uehara, Itoh, Arai, Takamiya, Suzuki, Kurachi (bb0295) 2011; 186 Kaddurah-Daouk, Krishnan (bb0145) 2009; 34 Horrobin (bb0125) 1998; 30 Lessig, Fuchs (bb0180) 2009; 16 Agostoni, Riva, Giovannini, Pinto, Colombo, Rise, Galli, Marangoni (bb0005) 2008; 93 Farooqui, Horrocks (bb0045) 2001; 7 Chen, Gross (bb0025) 1994; 33 Folch, Lees (bb4455) 1957; 226 Zeng, Han, Schlesinger, Gross (bb0325) 1998; 37 Ho, Andreasen, Nopoulos, Arndt, Magnotta, Flaum (bb0115) 2003; 60 Storey, Tibshirani (bb0290) 2003; 100 McHowat, Creer (bb0225) 2001; 1 Wojda, Salinska, Kuznicki (bb0355) 2008; 60 Watkins, Reifsnyder, Pan, German, Leiter (bb0305) 2002; 43 Ginsberg, Rafique, Xuereb, Rapoport, Gershfeld (bb0070) 1995; 698 Kaddurah-Daouk, Kristal, Weinshilboum (bb0150) 2008; 48 Grimm, Kuchenbecker, Rothhaar, Grosgen, Hundsdorfer, Burg, Friess, Muller, Grimm, Riemenschneider, Hartmann (bb0080) 2011; 116 Maeba, Ueta (bb0195) 2003; 302 Goodenowe, Cook, Liu, Lu, Jayasinghe, Ahiahonu, Heath, Yamazaki, Flax, Krenitsky, Sparks, Lerner, Friedland, Kudo, Kamino, Morihara, Takeda, Wood (bb0075) 2007; 48 Kaddurah-Daouk, McEvoy, Baillie, Lee, Yao, Doraiswamy, Krishnan (bb0155) 2007; 12 Hashimoto, Hossain, Tanabe, Shido (bb0105) 2005; 73 Horrobin, Manku, Hillman, Iain, Glen (bb0130) 1991; 30 Pettegrew, Panchalingam, Hamilton, McClure (bb0245) 2001; 26 Ji, Hebbring, Zhu, Jenkins, Biernacka, Snyder, Drews, Fiehn, Zeng, Schaid, Mrazek, Kaddurah-Daouk, Weinshilboum (bb0340) 2011; 89 Han (bb0090) 2005; 2 Clark, Lee, Rolston, Zhu, Marlatt, Castellani, Nunomura, Casadesus, Smith, Lee, Perry (bb0035) 2010; 6 Fox, Ross, Tocher, Horrobin, Glen, St Clair (bb0055) 2003; 69 Brosche, Brueckmann, Haase, Sieber, Bertsch (bb0015) 2007; 45 Stenvinkel, Holmberg, Heimburger, Diczfalusy (bb0285) 1998; 13 Hibbeln, Makino, Martin, Dickerson, Boronow, Fenton (bb0110) 2003; 53 Mazza, Pomponi, Janiri, Bria, Mazza (bb0220) 2007; 31 Yao, Leonard, Reddy (bb0315) 2000; 42 Andre (10.1016/j.psychres.2012.02.019_bb0010) 2005; 40 Pettegrew (10.1016/j.psychres.2012.02.019_bb0245) 2001; 26 Lohner (10.1016/j.psychres.2012.02.019_bb0190) 1996; 81 Wojda (10.1016/j.psychres.2012.02.019_bb0355) 2008; 60 Ji (10.1016/j.psychres.2012.02.019_bb0340) 2011; 89 Storey (10.1016/j.psychres.2012.02.019_bb0290) 2003; 100 Keshavan (10.1016/j.psychres.2012.02.019_bb0165) 1993; 49 Farooqui (10.1016/j.psychres.2012.02.019_bb0045) 2001; 7 Martinez (10.1016/j.psychres.2012.02.019_bb0215) 2000; 71 Han (10.1016/j.psychres.2012.02.019_bb0090) 2005; 2 Horrobin (10.1016/j.psychres.2012.02.019_bb0125) 1998; 30 Insel (10.1016/j.psychres.2012.02.019_bb0135) 2010; 468 Stenvinkel (10.1016/j.psychres.2012.02.019_bb0280) 2004; 19 Gross (10.1016/j.psychres.2012.02.019_bb0085) 1985; 24 Gaposchkin (10.1016/j.psychres.2012.02.019_bb0060) 1999; 40 Brosche (10.1016/j.psychres.2012.02.019_bb0020) 1998; 33 Stenvinkel (10.1016/j.psychres.2012.02.019_bb0285) 1998; 13 Kaddurah-Daouk (10.1016/j.psychres.2012.02.019_bb0145) 2009; 34 Rhoades (10.1016/j.psychres.2012.02.019_bb0270) 1988; 24 Kaddurah-Daouk (10.1016/j.psychres.2012.02.019_bb0150) 2008; 48 Fox (10.1016/j.psychres.2012.02.019_bb0055) 2003; 69 Pettegrew (10.1016/j.psychres.2012.02.019_bb0240) 1993; 19 Mahadik (10.1016/j.psychres.2012.02.019_bb0345) 2006 Clark (10.1016/j.psychres.2012.02.019_bb0035) 2010; 6 Kristal (10.1016/j.psychres.2012.02.019_bb0170) 2007; 358 Hartmann (10.1016/j.psychres.2012.02.019_bb0095) 2007; 103 Zivkovic (10.1016/j.psychres.2012.02.019_bb0330) 2009; 5 Reddy (10.1016/j.psychres.2012.02.019_bb0265) 2003; 69 Munn (10.1016/j.psychres.2012.02.019_bb0230) 2003; 44 Zeng (10.1016/j.psychres.2012.02.019_bb0325) 1998; 37 Cheng (10.1016/j.psychres.2012.02.019_bb0335) 2003; 49 Nuss (10.1016/j.psychres.2012.02.019_bb0235) 2009; 169 Falkai (10.1016/j.psychres.2012.02.019_bb0050) 1999; 25 McHowat (10.1016/j.psychres.2012.02.019_bb0225) 2001; 1 Geppert (10.1016/j.psychres.2012.02.019_bb0065) 2009; 82 Hibbeln (10.1016/j.psychres.2012.02.019_bb0110) 2003; 53 Hashimoto (10.1016/j.psychres.2012.02.019_bb0105) 2005; 73 Hashimoto (10.1016/j.psychres.2012.02.019_bb0100) 1999; 34 Ho (10.1016/j.psychres.2012.02.019_bb0115) 2003; 60 Kaddurah-Daouk (10.1016/j.psychres.2012.02.019_bb0160) 2011; 6 Yarlagadda (10.1016/j.psychres.2012.02.019_bb0320) 2002; 58 Lieberman (10.1016/j.psychres.2012.02.019_bb0185) 2005; 353 Mahadik (10.1016/j.psychres.2012.02.019_bb0210) 2001; 25 Ginsberg (10.1016/j.psychres.2012.02.019_bb0070) 1995; 698 Goodenowe (10.1016/j.psychres.2012.02.019_bb0075) 2007; 48 Lessig (10.1016/j.psychres.2012.02.019_bb0180) 2009; 16 Engelmann (10.1016/j.psychres.2012.02.019_bb0040) 1994; 1196 Reddy (10.1016/j.psychres.2012.02.019_bb0260) 2004; 30 Watkins (10.1016/j.psychres.2012.02.019_bb0305) 2002; 43 Pike (10.1016/j.psychres.2012.02.019_bb0250) 2002; 41 Sumiyoshi (10.1016/j.psychres.2012.02.019_bb0295) 2011; 186 Hoerrmann (10.1016/j.psychres.2012.02.019_bb0120) 1991; 20 R Development Core Team (10.1016/j.psychres.2012.02.019_bb0350) 2006 Wang-Sattler (10.1016/j.psychres.2012.02.019_bb0300) 2008; 3 Grimm (10.1016/j.psychres.2012.02.019_bb0080) 2011; 116 Horrobin (10.1016/j.psychres.2012.02.019_bb0130) 1991; 30 Schwarz (10.1016/j.psychres.2012.02.019_bb0275) 2008; 7 Chen (10.1016/j.psychres.2012.02.019_bb0025) 1994; 33 Yao (10.1016/j.psychres.2012.02.019_bb0315) 2000; 42 Kaddurah-Daouk (10.1016/j.psychres.2012.02.019_bb0155) 2007; 12 Folch (10.1016/j.psychres.2012.02.019_bb4455) 1957; 226 Agostoni (10.1016/j.psychres.2012.02.019_bb0005) 2008; 93 Brosche (10.1016/j.psychres.2012.02.019_bb0015) 2007; 45 Latorre (10.1016/j.psychres.2012.02.019_bb0175) 2003; 270 Maeba (10.1016/j.psychres.2012.02.019_bb0195) 2003; 302 Maeba (10.1016/j.psychres.2012.02.019_bb0200) 2004; 32 Mazza (10.1016/j.psychres.2012.02.019_bb0220) 2007; 31 |
| References_xml | – volume: 1196 start-page: 154 year: 1994 end-page: 164 ident: bb0040 article-title: Reversible reduction of phospholipid bound arachidonic acid after low density lipoprotein apheresis. Evidence for rapid incorporation of plasmalogen phosphatidylethanolamine into the red blood cell membrane publication-title: Biochimica et Biophysica Acta – volume: 103 start-page: 159 year: 2007 end-page: 170 ident: bb0095 article-title: Alzheimer's disease: the lipid connection publication-title: Journal of Neurochemistry – volume: 41 start-page: 2075 year: 2002 end-page: 2088 ident: bb0250 article-title: Lipid rafts are enriched in arachidonic acid and plasmenylethanolamine and their composition is independent of caveolin-1 expression: a quantitative electrospray ionization/mass spectrometric analysis publication-title: Biochemistry – volume: 31 start-page: 12 year: 2007 end-page: 26 ident: bb0220 article-title: Omega-3 fatty acids and antioxidants in neurological and psychiatric diseases: an overview publication-title: Progress in Neuro-Psychopharmacology & Biological Psychiatry – volume: 44 start-page: 182 year: 2003 end-page: 192 ident: bb0230 article-title: Deficiency in ethanolamine plasmalogen leads to altered cholesterol transport publication-title: Journal of Lipid Research – volume: 100 start-page: 9440 year: 2003 end-page: 9445 ident: bb0290 article-title: Statistical significance for genomewide studies publication-title: Proceedings of the National Academy of Sciences of the United States of America – volume: 2 start-page: 65 year: 2005 end-page: 77 ident: bb0090 article-title: Lipid alterations in the earliest clinically recognizable stage of Alzheimer's disease: implication of the role of lipids in the pathogenesis of Alzheimer's disease publication-title: Current Alzheimer Research – volume: 169 start-page: 91 year: 2009 end-page: 96 ident: bb0235 article-title: Abnormal transbilayer distribution of phospholipids in red blood cell membranes in schizophrenia publication-title: Psychiatry Research – volume: 25 start-page: 463 year: 2001 end-page: 493 ident: bb0210 article-title: Oxidative stress and role of antioxidant and omega-3 essential fatty acid supplementation in schizophrenia publication-title: Progress in Neuro-Psychopharmacology & Biological Psychiatry – volume: 6 start-page: e25482 year: 2011 ident: bb0160 article-title: Enteric microbiome correlates with response to simvastatin treatment publication-title: PLoS One – volume: 40 start-page: 495 year: 1999 end-page: 503 ident: bb0060 article-title: Plasmalogen status influences docosahexaenoic acid levels in a macrophage cell line. Insights using ether lipid-deficient variants publication-title: Journal of Lipid Research – volume: 116 start-page: 916 year: 2011 end-page: 925 ident: bb0080 article-title: Plasmalogen synthesis is regulated via alkyl-dihydroxyacetonephosphate-synthase by amyloid precursor protein processing and is affected in Alzheimer's disease publication-title: Journal of Neurochemistry – year: 2006 ident: bb0345 article-title: Phospholipids in schizophrenia publication-title: Textbook of Schizophrenia – volume: 30 start-page: 795 year: 1991 end-page: 805 ident: bb0130 article-title: Fatty acid levels in the brains of schizophrenics and normal controls publication-title: Biological Psychiatry – volume: 42 start-page: 7 year: 2000 end-page: 17 ident: bb0315 article-title: Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients publication-title: Schizophrenia Research – volume: 69 start-page: 291 year: 2003 end-page: 297 ident: bb0055 article-title: Degradation of specific polyunsaturated fatty acids in red blood cells stored at − publication-title: Prostaglandins, Leukotrienes, and Essential Fatty Acids – volume: 353 start-page: 1209 year: 2005 end-page: 1223 ident: bb0185 article-title: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia publication-title: The New England Journal of Medicine – volume: 24 start-page: 101 year: 1988 end-page: 104 ident: bb0270 article-title: The semistructured BPRS interview and rating guide publication-title: Psychopharmacology Bulletin – volume: 33 start-page: 13769 year: 1994 end-page: 13774 ident: bb0025 article-title: Phospholipid subclass-specific alterations in the kinetics of ion transport across biologic membranes publication-title: Biochemistry – volume: 33 start-page: 363 year: 1998 end-page: 369 ident: bb0020 article-title: The biological significance of plasmalogens in defense against oxidative damage publication-title: Experimental Gerontology – volume: 71 start-page: 376S year: 2000 end-page: 385S ident: bb0215 article-title: Therapeutic effects of docosahexaenoic acid ethyl ester in patients with generalized peroxisomal disorders publication-title: American Journal of Clinical Nutrition – volume: 69 start-page: 385 year: 2003 end-page: 391 ident: bb0265 article-title: Environmental factors and membrane polyunsaturated fatty acids in schizophrenia publication-title: Prostaglandins, Leukotrienes, and Essential Fatty Acids – volume: 45 start-page: 689 year: 2007 end-page: 691 ident: bb0015 article-title: Decreased plasmalogen concentration as a surrogate marker of oxidative stress in patients presenting with acute coronary syndromes or supraventricular tachycardias publication-title: Clinical Chemistry and Laboratory Medicine – volume: 26 start-page: 771 year: 2001 end-page: 782 ident: bb0245 article-title: Brain membrane phospholipid alterations in Alzheimer's disease publication-title: Neurochemical Research – volume: 60 start-page: 585 year: 2003 end-page: 594 ident: bb0115 article-title: Progressive structural brain abnormalities and their relationship to clinical outcome: a longitudinal magnetic resonance imaging study early in schizophrenia publication-title: Archives of General Psychiatry – volume: 270 start-page: 36 year: 2003 end-page: 46 ident: bb0175 article-title: Signaling events mediating activation of brain ethanolamine plasmalogen hydrolysis by ceramide publication-title: European Journal of Biochemistry – volume: 20 start-page: 319 year: 1991 end-page: 322 ident: bb0120 article-title: Serum plasmalogens in ischemic cerebrovascular disease publication-title: VASA – volume: 43 start-page: 1809 year: 2002 end-page: 1817 ident: bb0305 article-title: Lipid metabolome-wide effects of the PPARγ agonist rosiglitazone publication-title: Journal of Lipid Research – volume: 25 start-page: 48 year: 1999 end-page: 53 ident: bb0050 article-title: No evidence for astrogliosis in brains of schizophrenic patients. A post-mortem study publication-title: Neuropathology and Applied Neurobiology – volume: 7 start-page: 4266 year: 2008 end-page: 4277 ident: bb0275 article-title: High throughput lipidomic profiling of schizophrenia and bipolar disorder brain tissue reveals alterations of free fatty acids, phosphatidylcholines, and ceramides publication-title: Journal of Proteome Research – volume: 30 start-page: 901 year: 2004 end-page: 911 ident: bb0260 article-title: Reduced red blood cell membrane essential polyunsaturated fatty acids in first episode schizophrenia at neuroleptic-naive baseline publication-title: Schizophrenia Bulletin – volume: 16 start-page: 2021 year: 2009 end-page: 2041 ident: bb0180 article-title: Plasmalogens in biological systems: their role in oxidative processes in biological membranes, their contribution to pathological processes and aging and plasmalogen analysis publication-title: Current Medicinal Chemistry – volume: 82 start-page: 51 year: 2009 end-page: 56 ident: bb0065 article-title: Gender-specific fatty acid profiles in platelet phosphatidyl-choline and -ethanolamine publication-title: Prostaglandins, Leukotrienes, and Essential Fatty Acids – volume: 60 start-page: 575 year: 2008 end-page: 590 ident: bb0355 article-title: Calcium ions in neuronal degeneration publication-title: IUBMB Life – volume: 186 start-page: 23 year: 2011 end-page: 27 ident: bb0295 article-title: Membrane fatty acid levels as a predictor of treatment response in chronic schizophrenia publication-title: Psychiatry Research – volume: 5 start-page: 507 year: 2009 end-page: 516 ident: bb0330 article-title: Effects of sample handling and storage on quantitative lipid analysis in human serum publication-title: Metabolomics – volume: 698 start-page: 223 year: 1995 end-page: 226 ident: bb0070 article-title: Disease and anatomic specificity of ethanolamine plasmalogen deficiency in Alzheimer's disease brain publication-title: Brain Research – volume: 34 start-page: 173 year: 2009 end-page: 186 ident: bb0145 article-title: Metabolomics: a global biochemical approach to the study of central nervous system diseases publication-title: Neuropsychopharmacology – volume: 58 start-page: 182 year: 2002 end-page: 186 ident: bb0320 article-title: Role of calcium regulation in pathophysiology model of schizophrenia and possible interventions publication-title: Medical Hypotheses – volume: 468 start-page: 187 year: 2010 end-page: 193 ident: bb0135 article-title: Rethinking schizophrenia publication-title: Nature – volume: 226 start-page: 497 year: 1957 end-page: 509 ident: bb4455 article-title: A simple method for the isolation and purification of total lipides from animal tissues publication-title: The Journal of Biological Chemistry – volume: 30 start-page: 193 year: 1998 end-page: 208 ident: bb0125 article-title: The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia publication-title: Schizophrenia Research – volume: 49 start-page: 89 year: 1993 end-page: 95 ident: bb0165 article-title: Erythrocyte membrane phospholipids in psychotic patients publication-title: Psychiatry Research – volume: 19 start-page: 35 year: 1993 end-page: 53 ident: bb0240 article-title: 31P nuclear magnetic resonance spectroscopy: neurodevelopment and schizophrenia publication-title: Schizophrenia Bulletin – volume: 89 start-page: 97 year: 2011 end-page: 104 ident: bb0340 article-title: Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: pharmacometabolomics-informed pharmacogenomics publication-title: Clinical Pharmacology and Therapeutics – volume: 37 start-page: 9497 year: 1998 end-page: 9508 ident: bb0325 article-title: Nonesterified fatty acids induce transmembrane monovalent cation flux: host–guest interactions as determinants of fatty acid-induced ion transport publication-title: Biochemistry – volume: 7 start-page: 232 year: 2001 end-page: 245 ident: bb0045 article-title: Plasmalogens: workhorse lipids of membranes in normal and injured neurons and glia publication-title: The Neuroscientist – volume: 73 start-page: 475 year: 2005 end-page: 483 ident: bb0105 article-title: Effects of aging on the relation of adenyl purine release with plasma membrane fluidity of arterial endothelial cells publication-title: Prostaglandins, Leukotrienes, and Essential Fatty Acids – volume: 53 start-page: 431 year: 2003 end-page: 441 ident: bb0110 article-title: Smoking, gender, and dietary influences on erythrocyte essential fatty acid composition among patients with schizophrenia or schizoaffective disorder publication-title: Biological Psychiatry – volume: 1 start-page: 253 year: 2001 end-page: 265 ident: bb0225 article-title: Comparative roles of phospholipase A2 isoforms in cardiovascular pathophysiology publication-title: Cardiovascular Toxicology – volume: 40 start-page: 799 year: 2005 end-page: 806 ident: bb0010 article-title: Effects of aging and dietary n-3 fatty acids on rat brain phospholipids: focus on plasmalogens publication-title: Lipids – volume: 3 start-page: e3863 year: 2008 ident: bb0300 article-title: Metabolic profiling reveals distinct variations linked to nicotine consumption in humans—first results from the KORA study publication-title: PLoS One – volume: 93 start-page: 414 year: 2008 end-page: 418 ident: bb0005 article-title: Maternal smoking habits are associated with differences in infants' long-chain polyunsaturated fatty acids in whole blood: a case–control study publication-title: Archives of Disease in Childhood – volume: 12 start-page: 934 year: 2007 end-page: 945 ident: bb0155 article-title: Metabolomic mapping of atypical antipsychotic effects in schizophrenia publication-title: Molecular Psychiatry – year: 2006 ident: bb0350 article-title: R: A Language and Environment for Statistical Computing – volume: 81 start-page: 167 year: 1996 end-page: 184 ident: bb0190 article-title: Is the high propensity of ethanolamine plasmalogens to form non-lamellar lipid structures manifested in the properties of biomembranes? publication-title: Chemistry and Physics of Lipids – volume: 48 start-page: 2485 year: 2007 end-page: 2498 ident: bb0075 article-title: Peripheral ethanolamine plasmalogen deficiency: a logical causative factor in Alzheimer's disease and dementia publication-title: Journal of Lipid Research – volume: 24 start-page: 1662 year: 1985 end-page: 1668 ident: bb0085 article-title: Identification of plasmalogen as the major phospholipid constituent of cardiac sarcoplasmic reticulum publication-title: Biochemistry – volume: 13 start-page: 2594 year: 1998 end-page: 2600 ident: bb0285 article-title: A study of plasmalogen as an index of oxidative stress in patients with chronic renal failure. Evidence of increased oxidative stress in malnourished patients publication-title: Nephrology, Dialysis, Transplantation – volume: 32 start-page: 141 year: 2004 end-page: 143 ident: bb0200 article-title: A novel antioxidant action of ethanolamine plasmalogens in lowering the oxidizability of membranes publication-title: Biochemical Society Transactions – volume: 34 start-page: 687 year: 1999 end-page: 698 ident: bb0100 article-title: Effect of aging on plasma membrane fluidity of rat aortic endothelial cells publication-title: Experimental Gerontology – volume: 358 start-page: 159 year: 2007 end-page: 174 ident: bb0170 article-title: High-performance liquid chromatography separations coupled with coulometric electrode array detectors: a unique approach to metabolomics publication-title: Methods in Molecular Biology – volume: 302 start-page: 265 year: 2003 end-page: 270 ident: bb0195 article-title: Ethanolamine plasmalogen and cholesterol reduce the total membrane oxidizability measured by the oxygen uptake method publication-title: Biochemical and Biophysical Research Communications – volume: 49 start-page: 809 year: 2003 end-page: 818 ident: bb0335 article-title: Specificity and potential mechanism of sulfatide deficiency in Alzheimer's disease: an electrospray ionization mass spectrometric study publication-title: Cellular and Molecular Biology (Noisy-le-Grand, France) – volume: 6 start-page: 225 year: 2010 end-page: 227 ident: bb0035 article-title: Oxidative stress and its implications for future treatments and management of Alzheimer disease publication-title: International Journal of Biomedical Sciences – volume: 48 start-page: 653 year: 2008 end-page: 683 ident: bb0150 article-title: Metabolomics: a global biochemical approach to drug response and disease publication-title: Annual Review of Pharmacology and Toxicology – volume: 19 start-page: 972 year: 2004 end-page: 976 ident: bb0280 article-title: Phospholipid plasmalogen, a surrogate marker of oxidative stress, is associated with increased cardiovascular mortality in patients on renal replacement therapy publication-title: Nephrology, Dialysis, Transplantation – volume: 82 start-page: 51 year: 2009 ident: 10.1016/j.psychres.2012.02.019_bb0065 article-title: Gender-specific fatty acid profiles in platelet phosphatidyl-choline and -ethanolamine publication-title: Prostaglandins, Leukotrienes, and Essential Fatty Acids doi: 10.1016/j.plefa.2009.09.002 – volume: 71 start-page: 376S year: 2000 ident: 10.1016/j.psychres.2012.02.019_bb0215 article-title: Therapeutic effects of docosahexaenoic acid ethyl ester in patients with generalized peroxisomal disorders publication-title: American Journal of Clinical Nutrition doi: 10.1093/ajcn/71.1.376s – volume: 1 start-page: 253 year: 2001 ident: 10.1016/j.psychres.2012.02.019_bb0225 article-title: Comparative roles of phospholipase A2 isoforms in cardiovascular pathophysiology publication-title: Cardiovascular Toxicology doi: 10.1385/CT:1:4:253 – volume: 43 start-page: 1809 year: 2002 ident: 10.1016/j.psychres.2012.02.019_bb0305 article-title: Lipid metabolome-wide effects of the PPARγ agonist rosiglitazone publication-title: Journal of Lipid Research doi: 10.1194/jlr.M200169-JLR200 – volume: 60 start-page: 575 year: 2008 ident: 10.1016/j.psychres.2012.02.019_bb0355 article-title: Calcium ions in neuronal degeneration publication-title: IUBMB Life doi: 10.1002/iub.91 – volume: 1196 start-page: 154 year: 1994 ident: 10.1016/j.psychres.2012.02.019_bb0040 article-title: Reversible reduction of phospholipid bound arachidonic acid after low density lipoprotein apheresis. Evidence for rapid incorporation of plasmalogen phosphatidylethanolamine into the red blood cell membrane publication-title: Biochimica et Biophysica Acta doi: 10.1016/0005-2736(94)00227-4 – volume: 48 start-page: 653 year: 2008 ident: 10.1016/j.psychres.2012.02.019_bb0150 article-title: Metabolomics: a global biochemical approach to drug response and disease publication-title: Annual Review of Pharmacology and Toxicology doi: 10.1146/annurev.pharmtox.48.113006.094715 – volume: 100 start-page: 9440 year: 2003 ident: 10.1016/j.psychres.2012.02.019_bb0290 article-title: Statistical significance for genomewide studies publication-title: Proceedings of the National Academy of Sciences of the United States of America doi: 10.1073/pnas.1530509100 – year: 2006 ident: 10.1016/j.psychres.2012.02.019_bb0345 article-title: Phospholipids in schizophrenia – volume: 13 start-page: 2594 year: 1998 ident: 10.1016/j.psychres.2012.02.019_bb0285 article-title: A study of plasmalogen as an index of oxidative stress in patients with chronic renal failure. Evidence of increased oxidative stress in malnourished patients publication-title: Nephrology, Dialysis, Transplantation doi: 10.1093/ndt/13.10.2594 – volume: 58 start-page: 182 year: 2002 ident: 10.1016/j.psychres.2012.02.019_bb0320 article-title: Role of calcium regulation in pathophysiology model of schizophrenia and possible interventions publication-title: Medical Hypotheses doi: 10.1054/mehy.2001.1511 – volume: 25 start-page: 463 year: 2001 ident: 10.1016/j.psychres.2012.02.019_bb0210 article-title: Oxidative stress and role of antioxidant and omega-3 essential fatty acid supplementation in schizophrenia publication-title: Progress in Neuro-Psychopharmacology & Biological Psychiatry doi: 10.1016/S0278-5846(00)00181-0 – volume: 19 start-page: 972 year: 2004 ident: 10.1016/j.psychres.2012.02.019_bb0280 article-title: Phospholipid plasmalogen, a surrogate marker of oxidative stress, is associated with increased cardiovascular mortality in patients on renal replacement therapy publication-title: Nephrology, Dialysis, Transplantation doi: 10.1093/ndt/gfh035 – volume: 30 start-page: 193 year: 1998 ident: 10.1016/j.psychres.2012.02.019_bb0125 article-title: The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia publication-title: Schizophrenia Research doi: 10.1016/S0920-9964(97)00151-5 – volume: 103 start-page: 159 issue: Suppl. 1 year: 2007 ident: 10.1016/j.psychres.2012.02.019_bb0095 article-title: Alzheimer's disease: the lipid connection publication-title: Journal of Neurochemistry doi: 10.1111/j.1471-4159.2007.04715.x – volume: 698 start-page: 223 year: 1995 ident: 10.1016/j.psychres.2012.02.019_bb0070 article-title: Disease and anatomic specificity of ethanolamine plasmalogen deficiency in Alzheimer's disease brain publication-title: Brain Research doi: 10.1016/0006-8993(95)00931-F – volume: 3 start-page: e3863 year: 2008 ident: 10.1016/j.psychres.2012.02.019_bb0300 article-title: Metabolic profiling reveals distinct variations linked to nicotine consumption in humans—first results from the KORA study publication-title: PLoS One doi: 10.1371/journal.pone.0003863 – volume: 49 start-page: 89 year: 1993 ident: 10.1016/j.psychres.2012.02.019_bb0165 article-title: Erythrocyte membrane phospholipids in psychotic patients publication-title: Psychiatry Research doi: 10.1016/0165-1781(93)90032-C – volume: 169 start-page: 91 year: 2009 ident: 10.1016/j.psychres.2012.02.019_bb0235 article-title: Abnormal transbilayer distribution of phospholipids in red blood cell membranes in schizophrenia publication-title: Psychiatry Research doi: 10.1016/j.psychres.2009.01.009 – volume: 34 start-page: 687 year: 1999 ident: 10.1016/j.psychres.2012.02.019_bb0100 article-title: Effect of aging on plasma membrane fluidity of rat aortic endothelial cells publication-title: Experimental Gerontology doi: 10.1016/S0531-5565(99)00025-X – volume: 358 start-page: 159 year: 2007 ident: 10.1016/j.psychres.2012.02.019_bb0170 article-title: High-performance liquid chromatography separations coupled with coulometric electrode array detectors: a unique approach to metabolomics publication-title: Methods in Molecular Biology doi: 10.1007/978-1-59745-244-1_10 – volume: 30 start-page: 795 year: 1991 ident: 10.1016/j.psychres.2012.02.019_bb0130 article-title: Fatty acid levels in the brains of schizophrenics and normal controls publication-title: Biological Psychiatry doi: 10.1016/0006-3223(91)90235-E – volume: 41 start-page: 2075 year: 2002 ident: 10.1016/j.psychres.2012.02.019_bb0250 article-title: Lipid rafts are enriched in arachidonic acid and plasmenylethanolamine and their composition is independent of caveolin-1 expression: a quantitative electrospray ionization/mass spectrometric analysis publication-title: Biochemistry doi: 10.1021/bi0156557 – volume: 2 start-page: 65 year: 2005 ident: 10.1016/j.psychres.2012.02.019_bb0090 article-title: Lipid alterations in the earliest clinically recognizable stage of Alzheimer's disease: implication of the role of lipids in the pathogenesis of Alzheimer's disease publication-title: Current Alzheimer Research doi: 10.2174/1567205052772786 – volume: 33 start-page: 363 year: 1998 ident: 10.1016/j.psychres.2012.02.019_bb0020 article-title: The biological significance of plasmalogens in defense against oxidative damage publication-title: Experimental Gerontology doi: 10.1016/S0531-5565(98)00014-X – volume: 53 start-page: 431 year: 2003 ident: 10.1016/j.psychres.2012.02.019_bb0110 article-title: Smoking, gender, and dietary influences on erythrocyte essential fatty acid composition among patients with schizophrenia or schizoaffective disorder publication-title: Biological Psychiatry doi: 10.1016/S0006-3223(02)01549-4 – volume: 5 start-page: 507 year: 2009 ident: 10.1016/j.psychres.2012.02.019_bb0330 article-title: Effects of sample handling and storage on quantitative lipid analysis in human serum publication-title: Metabolomics doi: 10.1007/s11306-009-0174-2 – volume: 20 start-page: 319 year: 1991 ident: 10.1016/j.psychres.2012.02.019_bb0120 article-title: Serum plasmalogens in ischemic cerebrovascular disease publication-title: VASA – volume: 49 start-page: 809 year: 2003 ident: 10.1016/j.psychres.2012.02.019_bb0335 article-title: Specificity and potential mechanism of sulfatide deficiency in Alzheimer's disease: an electrospray ionization mass spectrometric study publication-title: Cellular and Molecular Biology (Noisy-le-Grand, France) – volume: 24 start-page: 1662 year: 1985 ident: 10.1016/j.psychres.2012.02.019_bb0085 article-title: Identification of plasmalogen as the major phospholipid constituent of cardiac sarcoplasmic reticulum publication-title: Biochemistry doi: 10.1021/bi00328a014 – volume: 93 start-page: 414 year: 2008 ident: 10.1016/j.psychres.2012.02.019_bb0005 article-title: Maternal smoking habits are associated with differences in infants' long-chain polyunsaturated fatty acids in whole blood: a case–control study publication-title: Archives of Disease in Childhood doi: 10.1136/adc.2007.129817 – volume: 24 start-page: 101 year: 1988 ident: 10.1016/j.psychres.2012.02.019_bb0270 article-title: The semistructured BPRS interview and rating guide publication-title: Psychopharmacology Bulletin – volume: 73 start-page: 475 year: 2005 ident: 10.1016/j.psychres.2012.02.019_bb0105 article-title: Effects of aging on the relation of adenyl purine release with plasma membrane fluidity of arterial endothelial cells publication-title: Prostaglandins, Leukotrienes, and Essential Fatty Acids doi: 10.1016/j.plefa.2005.07.007 – volume: 19 start-page: 35 year: 1993 ident: 10.1016/j.psychres.2012.02.019_bb0240 article-title: 31P nuclear magnetic resonance spectroscopy: neurodevelopment and schizophrenia publication-title: Schizophrenia Bulletin doi: 10.1093/schbul/19.1.35 – volume: 12 start-page: 934 year: 2007 ident: 10.1016/j.psychres.2012.02.019_bb0155 article-title: Metabolomic mapping of atypical antipsychotic effects in schizophrenia publication-title: Molecular Psychiatry doi: 10.1038/sj.mp.4002000 – volume: 6 start-page: 225 year: 2010 ident: 10.1016/j.psychres.2012.02.019_bb0035 article-title: Oxidative stress and its implications for future treatments and management of Alzheimer disease publication-title: International Journal of Biomedical Sciences doi: 10.59566/IJBS.2010.6225 – volume: 37 start-page: 9497 year: 1998 ident: 10.1016/j.psychres.2012.02.019_bb0325 article-title: Nonesterified fatty acids induce transmembrane monovalent cation flux: host–guest interactions as determinants of fatty acid-induced ion transport publication-title: Biochemistry doi: 10.1021/bi980303u – volume: 81 start-page: 167 year: 1996 ident: 10.1016/j.psychres.2012.02.019_bb0190 article-title: Is the high propensity of ethanolamine plasmalogens to form non-lamellar lipid structures manifested in the properties of biomembranes? publication-title: Chemistry and Physics of Lipids doi: 10.1016/0009-3084(96)02580-7 – volume: 44 start-page: 182 year: 2003 ident: 10.1016/j.psychres.2012.02.019_bb0230 article-title: Deficiency in ethanolamine plasmalogen leads to altered cholesterol transport publication-title: Journal of Lipid Research doi: 10.1194/jlr.M200363-JLR200 – volume: 6 start-page: e25482 issue: 10 year: 2011 ident: 10.1016/j.psychres.2012.02.019_bb0160 article-title: Enteric microbiome correlates with response to simvastatin treatment publication-title: PLoS One doi: 10.1371/journal.pone.0025482 – volume: 16 start-page: 2021 year: 2009 ident: 10.1016/j.psychres.2012.02.019_bb0180 article-title: Plasmalogens in biological systems: their role in oxidative processes in biological membranes, their contribution to pathological processes and aging and plasmalogen analysis publication-title: Current Medicinal Chemistry doi: 10.2174/092986709788682164 – year: 2006 ident: 10.1016/j.psychres.2012.02.019_bb0350 – volume: 270 start-page: 36 year: 2003 ident: 10.1016/j.psychres.2012.02.019_bb0175 article-title: Signaling events mediating activation of brain ethanolamine plasmalogen hydrolysis by ceramide publication-title: European Journal of Biochemistry doi: 10.1046/j.1432-1033.2003.03356.x – volume: 7 start-page: 232 year: 2001 ident: 10.1016/j.psychres.2012.02.019_bb0045 article-title: Plasmalogens: workhorse lipids of membranes in normal and injured neurons and glia publication-title: The Neuroscientist doi: 10.1177/107385840100700308 – volume: 32 start-page: 141 year: 2004 ident: 10.1016/j.psychres.2012.02.019_bb0200 article-title: A novel antioxidant action of ethanolamine plasmalogens in lowering the oxidizability of membranes publication-title: Biochemical Society Transactions doi: 10.1042/bst0320141 – volume: 40 start-page: 495 year: 1999 ident: 10.1016/j.psychres.2012.02.019_bb0060 article-title: Plasmalogen status influences docosahexaenoic acid levels in a macrophage cell line. Insights using ether lipid-deficient variants publication-title: Journal of Lipid Research doi: 10.1016/S0022-2275(20)32454-8 – volume: 468 start-page: 187 year: 2010 ident: 10.1016/j.psychres.2012.02.019_bb0135 article-title: Rethinking schizophrenia publication-title: Nature doi: 10.1038/nature09552 – volume: 30 start-page: 901 year: 2004 ident: 10.1016/j.psychres.2012.02.019_bb0260 article-title: Reduced red blood cell membrane essential polyunsaturated fatty acids in first episode schizophrenia at neuroleptic-naive baseline publication-title: Schizophrenia Bulletin doi: 10.1093/oxfordjournals.schbul.a007140 – volume: 42 start-page: 7 year: 2000 ident: 10.1016/j.psychres.2012.02.019_bb0315 article-title: Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients publication-title: Schizophrenia Research doi: 10.1016/S0920-9964(99)00095-X – volume: 69 start-page: 291 year: 2003 ident: 10.1016/j.psychres.2012.02.019_bb0055 article-title: Degradation of specific polyunsaturated fatty acids in red blood cells stored at −20°C proceeds faster in patients with schizophrenia when compared with healthy controls publication-title: Prostaglandins, Leukotrienes, and Essential Fatty Acids doi: 10.1016/S0952-3278(03)00084-X – volume: 45 start-page: 689 year: 2007 ident: 10.1016/j.psychres.2012.02.019_bb0015 article-title: Decreased plasmalogen concentration as a surrogate marker of oxidative stress in patients presenting with acute coronary syndromes or supraventricular tachycardias publication-title: Clinical Chemistry and Laboratory Medicine doi: 10.1515/CCLM.2007.111 – volume: 33 start-page: 13769 year: 1994 ident: 10.1016/j.psychres.2012.02.019_bb0025 article-title: Phospholipid subclass-specific alterations in the kinetics of ion transport across biologic membranes publication-title: Biochemistry doi: 10.1021/bi00250a030 – volume: 89 start-page: 97 issue: 1 year: 2011 ident: 10.1016/j.psychres.2012.02.019_bb0340 article-title: Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: pharmacometabolomics-informed pharmacogenomics publication-title: Clinical Pharmacology and Therapeutics doi: 10.1038/clpt.2010.250 – volume: 40 start-page: 799 year: 2005 ident: 10.1016/j.psychres.2012.02.019_bb0010 article-title: Effects of aging and dietary n-3 fatty acids on rat brain phospholipids: focus on plasmalogens publication-title: Lipids doi: 10.1007/s11745-005-1441-x – volume: 25 start-page: 48 year: 1999 ident: 10.1016/j.psychres.2012.02.019_bb0050 article-title: No evidence for astrogliosis in brains of schizophrenic patients. A post-mortem study publication-title: Neuropathology and Applied Neurobiology doi: 10.1046/j.1365-2990.1999.00162.x – volume: 116 start-page: 916 year: 2011 ident: 10.1016/j.psychres.2012.02.019_bb0080 article-title: Plasmalogen synthesis is regulated via alkyl-dihydroxyacetonephosphate-synthase by amyloid precursor protein processing and is affected in Alzheimer's disease publication-title: Journal of Neurochemistry doi: 10.1111/j.1471-4159.2010.07070.x – volume: 48 start-page: 2485 year: 2007 ident: 10.1016/j.psychres.2012.02.019_bb0075 article-title: Peripheral ethanolamine plasmalogen deficiency: a logical causative factor in Alzheimer's disease and dementia publication-title: Journal of Lipid Research doi: 10.1194/jlr.P700023-JLR200 – volume: 353 start-page: 1209 year: 2005 ident: 10.1016/j.psychres.2012.02.019_bb0185 article-title: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia publication-title: The New England Journal of Medicine doi: 10.1056/NEJMoa051688 – volume: 69 start-page: 385 year: 2003 ident: 10.1016/j.psychres.2012.02.019_bb0265 article-title: Environmental factors and membrane polyunsaturated fatty acids in schizophrenia publication-title: Prostaglandins, Leukotrienes, and Essential Fatty Acids doi: 10.1016/j.plefa.2003.08.009 – volume: 34 start-page: 173 year: 2009 ident: 10.1016/j.psychres.2012.02.019_bb0145 article-title: Metabolomics: a global biochemical approach to the study of central nervous system diseases publication-title: Neuropsychopharmacology doi: 10.1038/npp.2008.174 – volume: 26 start-page: 771 year: 2001 ident: 10.1016/j.psychres.2012.02.019_bb0245 article-title: Brain membrane phospholipid alterations in Alzheimer's disease publication-title: Neurochemical Research doi: 10.1023/A:1011603916962 – volume: 226 start-page: 497 issue: 1 year: 1957 ident: 10.1016/j.psychres.2012.02.019_bb4455 article-title: A simple method for the isolation and purification of total lipides from animal tissues publication-title: The Journal of Biological Chemistry doi: 10.1016/S0021-9258(18)64849-5 – volume: 60 start-page: 585 year: 2003 ident: 10.1016/j.psychres.2012.02.019_bb0115 article-title: Progressive structural brain abnormalities and their relationship to clinical outcome: a longitudinal magnetic resonance imaging study early in schizophrenia publication-title: Archives of General Psychiatry doi: 10.1001/archpsyc.60.6.585 – volume: 186 start-page: 23 year: 2011 ident: 10.1016/j.psychres.2012.02.019_bb0295 article-title: Membrane fatty acid levels as a predictor of treatment response in chronic schizophrenia publication-title: Psychiatry Research doi: 10.1016/j.psychres.2010.07.049 – volume: 302 start-page: 265 year: 2003 ident: 10.1016/j.psychres.2012.02.019_bb0195 article-title: Ethanolamine plasmalogen and cholesterol reduce the total membrane oxidizability measured by the oxygen uptake method publication-title: Biochemical and Biophysical Research Communications doi: 10.1016/S0006-291X(03)00157-8 – volume: 31 start-page: 12 year: 2007 ident: 10.1016/j.psychres.2012.02.019_bb0220 article-title: Omega-3 fatty acids and antioxidants in neurological and psychiatric diseases: an overview publication-title: Progress in Neuro-Psychopharmacology & Biological Psychiatry doi: 10.1016/j.pnpbp.2006.07.010 – volume: 7 start-page: 4266 year: 2008 ident: 10.1016/j.psychres.2012.02.019_bb0275 article-title: High throughput lipidomic profiling of schizophrenia and bipolar disorder brain tissue reveals alterations of free fatty acids, phosphatidylcholines, and ceramides publication-title: Journal of Proteome Research doi: 10.1021/pr800188y |
| SSID | ssj0002199 |
| Score | 2.3075795 |
| Snippet | Plasmalogens are a subclass of glycerophospholipids and ubiquitous constituents of cellular membranes and serum lipoproteins. Several neurological disorders... Abstract Plasmalogens are a subclass of glycerophospholipids and ubiquitous constituents of cellular membranes and serum lipoproteins. Several neurological... |
| SourceID | proquest pubmed pascalfrancis crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 347 |
| SubjectTerms | Adult Adult and adolescent clinical studies Age Factors Biological and medical sciences Biomarkers - blood Body Mass Index Case-Control Studies Chronic Disease Drug-naïve Female Humans Lipidomics Male Medical sciences Metabolomics Metabolomics - methods Phosphatidylcholines - metabolism Phosphatidylethanolamines - metabolism Phospholipids Plasmalogen Plasmalogens - blood Psychiatric Status Rating Scales - statistics & numerical data Psychiatry Psychology. Psychoanalysis. Psychiatry Psychopathology. Psychiatry Psychoses Schizophrenia Schizophrenia - blood Sex Characteristics |
| Title | Impaired plasmalogens in patients with schizophrenia |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0165178112001011 https://www.clinicalkey.es/playcontent/1-s2.0-S0165178112001011 https://dx.doi.org/10.1016/j.psychres.2012.02.019 https://www.ncbi.nlm.nih.gov/pubmed/22513041 https://www.proquest.com/docview/1151700026 |
| Volume | 198 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8QwEB5EQQQR366PpYLXum2avo6yKKuiFxW8heYFK9pd7Hr1tzvTpruKiqLQS0uGJpOZyTfJzATgiGujrFGZr_M48rmSzJfoNfhJkKuc2ziThhKcr66TwR2_uI_v56Df5sJQWKWz_Y1Nr621-9Jz3OyNh8PeDSXihJQoyepCaXUGO0-pfv7x6yzMgzV3SFJjn1q_yxJ-OK4jitGtpRAvVtfupIo7Xy9Qy-OiQrbZ5r6L7wFpvTCdrcKKQ5TeSdPpNZgz5TosXrkz8w3g56jxOEjtjREpP9FmDbqu3rD0XE3VyqPNWK96H363CXdnp7f9ge_uSvAVQqyJr0KTqdRaxrRmrIiDglmFuiVZILM8i5OUJ4ZbbhEx2FziFFChPq1xijSu-DbagvlyVJod8KKkMDphMmGWvD8lEURwRXulLEY0lHUgbhkklCskTvdZPIo2YuxBtIwVxFgR4BPmHehN6cZNKY0fKdKW_6JNFEXTJtDa_43SVE5DKxGKCluKT1LUgXxK-UEQf_XX7gchmQ4TUVCEQAkbHLZSI1CN6WymKM3oBbuDyCslcU06sN2I04wauR4FPNz9R9f2YIneaDc8jPdhfvL8Yg4QTk1kt9aXLiycnF8Ort8AZsAfMw |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3dS-QwEB9EwRNE1Dt1_boKvtZt06QfjyLK-rG-qOBbaL5g5a4udn31b3emTVflFA-FPrUZmkxmJr9JZiYA-9xY7azOQ1OIJORasVCh1xCmUaEL7kSuLCU4Dy_TwQ0_uxW3M3DU5cJQWKW3_a1Nb6y1f9P33OyPR6P-FSXixJQoyZpCaegCzXGRZCTaB08vcR6svUSSWofU_FWa8N1BE1KMfi3FeLGmeCeV3Hl_hVoclzXyzbUXXnyMSJuV6WQZljykDA7bXq_AjK1WYX7oD81_Aj9FlcdRmmCMUPkv7dag7xqMqsAXVa0D2o0N6tfxd7_g5uT4-mgQ-ssSQo0YaxLq2OY6c44xYxgrRVQyp1G5FItUXuQizXhqueMOIYMrFM4BVeozBufI4JLvkjWYre4ruwFBkpbWpEylzJH7pxWiCK5ps5QJhEN5D0THIKl9JXG60OKP7ELG7mTHWEmMlRE-cdGD_pRu3NbS-JQi6_gvu0xRtG0Szf3XKG3tVbSWsayxpfxHjHpQTCnfSOJ__XX3jZBMh4kwKEGkhA32OqmRqMd0OFNW9v4Ru4PQKyNxTXuw3orTCzVyPYl4vPmNrv2GH4Pr4YW8OL0834IF-kJb47HYhtnJw6PdQWw1UbuN7jwD2owgyQ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Impaired+plasmalogens+in+patients+with+schizophrenia&rft.jtitle=Psychiatry+research&rft.au=KADDURAH-DAOUK%2C+Rima&rft.au=MCEVOY%2C+Joseph&rft.au=BAILLIE%2C+Rebecca&rft.au=HONGJIE+ZHU&rft.date=2012-08-15&rft.pub=Elsevier&rft.issn=0165-1781&rft.eissn=1872-7123&rft.volume=198&rft.issue=3&rft.spage=347&rft.epage=352&rft_id=info:doi/10.1016%2Fj.psychres.2012.02.019&rft.externalDBID=n%2Fa&rft.externalDocID=26631529 |
| thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F01651781%2FS0165178112X00118%2Fcov150h.gif |